General information
| Name: Akram |
| Surname: Alian |
| E-mail: alian@tx.yechnion.ac.il |
| Cell phone number with international prefix: +972-55-666-4838 |
| Country: Israel |
| Affiliation: Technion – Israel Institute of Technology |
| Gender: M |
| Year of the PhD title: 2002 |
| Personal web page: http://alian.net.technion.ac.il/ |
| Previous COST participation: Yes |
List of 10 selected publications within last 5 years
| 1. Marx A. Galilee M. and Alian A. Zinc enhancement of cytidine deaminase activity highlights a potential allosteric role of loop-3 in regulating APOBEC3 enzymes. 2015 Scientific Reports, 5: 18191 |
| 2. Eliahoo E., Marx A., Manor H., and Alian A. A Novel Open-Barrel Structure of Octameric Translin Reveals a Potential RNA Entryway. 2015 J. Mol. Biol., 427: 756-762. |
| 3. Marx A. and Alian A. The first crystal structure of a dTTP bound deoxycytidylate deaminase validates and details the allosteric-inhibitor binding site. 2015 J. Biol. Chem.. 290: 682-690 |
| 4. Galilee A. and Alian A. Identification of Phe187 as a Crucial Dimerization Determinant Facilitates Crystallization of a Monomeric Retroviral Integrase Core Domain. 2014, Structure, 22: 1512-1519. |
| 5. Czudnochowski N, Ashley G, Santi D, Alian A, Finer-Moore J, and Stroud RM. The mechanism of pseudouridine synthases from a covalent complex with RNA, and alternate specificity for U2605 versus U2604 between close homologs. 2014, Nucleic Acids Res., 42: 2037-2048 |
| 6. Wu S, Avila-Sakar A, Kim J, Booth DS, Greenberg CH, Rossi A, Liao M, Alian A, Griner SL, Juge N, Yu Y, Merge CM, Chaparro-Riggers J, Strop P, Tampé R, Edwards RH, Stroud RM, Craik CS, Cheng Y. Fabs enable high-resolution single particle cryoEM studies of small proteins. 2012, Structure, 20: 582-592. |
| 7. Marx A. and Alian A. Rerouting Resistance: Escaping Restriction Using Alternative Cellular Pathways. 2015 Trends in Microbiology, 23: 595-597. |
| 8. Marx A. and Alian A. The road less traveled: HIV’s use of alternative routes through cellular pathways. 2015 Journal of Virology, 89: 5204-5212. |
| 9. Alian A. and Aqeilan RI. T538 phosphorylation, Pin-ing p63-Itch stability. 2015 Cell Cycle, 15:0 |
| 10. Zaidoun S, Alian A, and Aqeilan RI. WW domain-containing proteins: Retrospectives and the future. 2012 Front. Biosci., 17: 331-348. |
Main skills and expertise (up to 5)
| 1. Macromolecule X-ray Crystallography |
| 2. Biochemistry (protein chromatography, enzymatic activities) |
| 3. Protein-ligand (DNA/RNA, small molecule, protein complexes) interactions (pull down, chromatography, FRET, MST thermophoresis, ITC, TSA-Thermofluorescence) |
| 4. Retrovirology; DNA/RNA modifying enzymes (methylation, peudouridination); enzyme-substrate specificity; structure-function relationship |
| 5. |
Main equipment/facilities available in the participants’ lab (up to 5)
| 1. X-ray crystallography (TTP Mosquito drop dispenser; Rigaku FRX X-ray diffractormeter) |
| 2. Molecular interactions (Monolith ITC; NanoTemp MST thermophoresis) |
| 3. Molecular Biology (PCR, Western Blot, protein expression in bacteria) |
| 4. Biochemistry (Chromatography AKTA-AVANT; Fluorescence plate reader) |
| 5. Mammalian tissue culture and viruses room (BSL 2+) |
Short personal activity proposal for the COST Action CA15135 (max 1000 characters)
| My have expertise in X-ray crystallography of macromolecules related to infectious pathogens and cancer, as well as in enzymatic activities and relating structure to function. Recently I proposed a novel hyothesis, viral rerouting-resistance, in which I suggest that the multiple pathways targeted by viruses must be identified and simulatneously targeted at multilevels. This COST action suggests a similar idea of developing the drugs to traget multiple targets at the same time.
Joining this COST action will expose me to the medicinal chemists society, which I am eager to collaborate and sure of fruitful outcome. I can contribute with my expertise using X-ray crystallograpy, structure-function analysis and structure-based drug desing to help increasing drug potencies.
|
Work Group preference: score from 1 (preferred) to 4 (not preferred)
| Work Group of the CA15135 COST Action | Score |
| WG1: Development of new chemical entities | 1 |
| WG2: Selection of biological targets and assessment of biological data | 2 |
| WG3: Development of chemical databases | 4 |
| WG4: Development of Computational methods for multiple ligand design and discovery | 4 |
